SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Use of signal detection methods to identify associations between prenatal medication exposure and subsequent childhood cancers: a Nordic hypothesis-generating registry-based study.

Johnson, H; Hjorth, S; Morris, J; Pottegård, A; Leinonen, M; Norby, U; Nordeng, H (2025) Use of signal detection methods to identify associations between prenatal medication exposure and subsequent childhood cancers: a Nordic hypothesis-generating registry-based study. Expert Opin Drug Saf. ISSN 1744-764X https://doi.org/10.1080/14740338.2025.2461204
SGUL Authors: Morris, Joan Katherine

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution.

Download (2MB) | Preview
[img] Microsoft Word (.docx) (Supplemental material) Supplemental Material
Download (4MB)

Abstract

BACKGROUND: Childhood cancer is an important contributor to childhood mortality in high income countries. Information on associations between childhood cancer and in-utero exposure is absent or limited for most medications. Signal detection methods identify medications where research should be focused but have not been applied to datasets containing prenatal medication exposures and childhood cancers. RESEARCH DESIGN AND METHODS: The aim of this study was to apply and evaluate four signal detection methods - odds ratios (OR), the information component (IC), sequential probability ratio testing (SPRT), and Bayesian hierarchical models (BHM) - for identification of associations between medications dispensed during pregnancy and subsequent, incident diagnosis of childhood cancer <10 years, using linked Nordic registry data. Signal detection results were compared to propensity score adjusted odds ratios from generalized linear models. RESULTS: Analysis was performed for 117 medication-cancer pairs with 5 or more observations. The OR had the greatest sensitivity (0.75). The IC had a greater specificity (0.98) than the OR (0.95). CONCLUSIONS: The IC may be the most appropriate method for identifying signals within this type of data. Reported signals should not be considered sufficient evidence of causal association and must be followed-up by tailored investigations that consider confounding by indication.

Item Type: Article
Additional Information: © 2025 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.
Keywords: Pharmacovigilance, Signal detection, childhood cancer, disproportionality analysis, medication in pregnancy, nordic registry data, prenatal exposure, 1007 Nanotechnology, 1115 Pharmacology and Pharmaceutical Sciences, Pharmacology & Pharmacy
SGUL Research Institute / Research Centre: Academic Structure > Population Health Research Institute (INPH)
Journal or Publication Title: Expert Opin Drug Saf
ISSN: 1744-764X
Language: eng
Publisher License: Creative Commons: Attribution 4.0
Projects:
Project IDFunderFunder ID
R275-A15824Nordic Cancer UnionUNSPECIFIED
MR/N013638/1Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
322176International Alliance for PharmaoGenetic Epidemiology ExcellenceUNSPECIFIED
PubMed ID: 39927430
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/117212
Publisher's version: https://doi.org/10.1080/14740338.2025.2461204

Actions (login required)

Edit Item Edit Item